{"links":{"html":"https://www.erudio.com/reports/bricket-nct06578559","json":"https://www.erudio.com/reports/bricket-nct06578559.json","markdown":"https://www.erudio.com/reports/bricket-nct06578559.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"bricket-06578559"}},"request":"https://www.erudio.com/contact?report=bricket-06578559"},"offer":{"cited_commentary_sources":11,"verified_hcp_statements":21,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":10,"optional":true,"price_per_verified_person_usd":15,"price_usd":150,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"bricket-nct06578559"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=bricket-06578559","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/bricket-nct06578559","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-28T22:38:46.230100Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: 10 people matched to verified clinician profiles (was 12); the sample findings."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":1},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Objective Response Rate (ORR)"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":5,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":1,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":1,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":1,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":5,"coverage":"discussed","id":"A1","source_count":5,"title":"What ctDNA selection can—and cannot—show"},{"claim_count":5,"coverage":"discussed","id":"A2","source_count":1,"title":"Continuing EC while switching chemotherapy after progression"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":1,"title":"Evidence threshold and alternatives before routine adoption"},{"claim_count":3,"coverage":"discussed","id":"A4","source_count":2,"title":"Durability beyond positive/negative trial labels"},{"claim_count":2,"coverage":"discussed","id":"A5","source_count":2,"title":"Development rationale and post-BREAKWATER research questions"}],"counts":{"cited_sources":12,"claims_by_expression_type":{"comparison":3,"experience":1,"interpretation":7,"opinion":5,"primary_context":2,"question":1,"restatement":1,"uncertainty":1},"claims_by_kind":{"attributed_opinion":14,"counterview":1,"limitation":1,"protocol_statement":1,"source_observation":4},"clinician_statements":8,"evidence_units":23,"findings":5,"organisational_accounts":1,"people_cited":11,"people_identity_verified":10,"people_total":13,"screened_sources":25,"verified_claims":21},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":0,"views":6},"has_counterview":true,"limitations":3,"links":{"context":5,"support":8},"ma_question":true,"named_voices":6,"passages":8,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Continuing EC with a chemotherapy switch attracts support, explicitly as extrapolation"},{"id":"F2","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":4},"ma_question":false,"named_voices":3,"passages":4,"sources":4,"sources_by_kind":{"commentary":3,"registry":1}},"title":"The negative reading concerns EC retreatment, with the conclusion kept tentative"},{"id":"F3","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":3},"has_counterview":false,"limitations":4,"links":{"context":0,"support":5},"ma_question":true,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"registry":1}},"title":"Insufficient molecular selection and no testing benefit are different conclusions"},{"id":"F4","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":0},"has_counterview":false,"limitations":4,"links":{"context":1,"support":4},"ma_question":true,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"registry":1}},"title":"Durability and small-study limitations challenge positive/negative labels"},{"id":"F5","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Research rationale persists without a claim of demonstrated retreatment benefit"}],"medical_affairs_question":"What comparative evidence would justify continued EC with a chemotherapy switch, and what can BRICKET actually establish about ctDNA-guided treatment benefit?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Continuing EC with a chemotherapy switch attracts support, explicitly as extrapolation"},{"id":"section-2","level":2,"title":"The negative reading concerns EC retreatment, with the conclusion kept tentative"},{"id":"section-3","level":2,"title":"Insufficient molecular selection and no testing benefit are different conclusions"},{"id":"section-4","level":2,"title":"Durability and small-study limitations challenge positive/negative labels"},{"id":"section-5","level":2,"title":"Research rationale persists without a claim of demonstrated retreatment benefit"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":1}],"id":"T1","label":"Primary endpoint: Objective Response Rate (ORR)"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":2},{"id":"F5","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F4","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F4","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-28T22:38:46.230100Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-28T23:07:02Z","record_hash":"b1323d559583e011f24f983ee06b62fcdaf7a3edffd9d94e2fc8fd0911e9985a","release_hash":"4ac064818a5a5e139af54cf85c6346d6cdedd8b24e3744f4310b4e1809d30052","report_id":"erudio-nct06578559","run_id":"1044a824-f3ed-4c49-9ee2-b674bc3773df","schema_version":"5.0","slug":"bricket-06578559","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"BRICKET asks whether blood-test-guided encorafenib plus cetuximab retreatment benefits patients with BRAF V600E-mutated metastatic colorectal cancer after earlier benefit from the combination. Clinicians in the sources reviewed question retreatment, while support for continuing targeted therapy with a chemotherapy switch remains conditional. That alternative attracts interest; molecular selection and durability draw scrutiny. Treatment after progression remains an open research question. The sources reviewed for this edition place the trial’s main results at ESMO 2026.","meta_description":"25 sources screened · 21 verified statements (8 from clinicians verified by NPI or staff page) from 12 sources · 5 findings. Updated Oct 28, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-635378597f7e07f51e4a"],"id":"F4","paraphrase":"An X post poses a cross-study interpretation question, rather than reporting a head-to-head comparison.","source_channel":"x_thread","source_date":"2026-10-24","title":"Durability and small-study limitations challenge positive/negative labels"},{"cited_claim_ids":["claim-9eb6223569684f8a10db"],"id":"F1","paraphrase":"An X discussion poses an analogy as a question, rather than reporting a tested comparison.","source_channel":"x_thread","source_date":"2026-10-24","title":"Continuing EC with a chemotherapy switch attracts support, explicitly as extrapolation"}]},"publication":{"approved_at":"2026-10-28T23:07:02Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-29T00:04:19Z","summary":"Corrected to match the delivered report: 10 people matched to verified clinician profiles (was 12); the sample findings."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":25},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition are X posts and quoted or linked material, not a representative sample of HCP practice. Reposts and duplicate quotations are not additional independent opinions.","The search emphasized the trial identifier and names; unnamed references and transcription variants may have been missed. More than 2,000 sources without the trial name were not read, and one potentially relevant discussion was not fully assessed.","No separate protocol was listed and no BRICKET results publication was identified. Reported numerical outcomes therefore describe what authors said, not a full appraisal of trial results.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","No substantive safety or tolerability commentary was identified in the reviewed material. This does not establish an absence of toxicity or a favorable benefit–harm balance.","Post dates do not establish presentation dates, changes of mind or disagreement across different settings.","Cross-study PFS comparisons and biological explanations offered in the posts do not establish comparative efficacy or causal resistance mechanisms."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":11,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":11,"methods":1},"count":12,"evidence_window":{"end":"2026-10-24","start":"2023-10-23"},"retrieval_snapshot":"2026-10-28T21:09:57.889073Z","timeline":[{"count":1,"week":"2023-W43"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W35"},{"count":1,"week":"2026-W41"},{"count":8,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06578559:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06578559:context","quote_policy":"short_quote_link_out"},{"id":"openfda:8bc6397e-4bd8-4d37-a007-a327e4da34d9:20260416","quote_policy":"short_quote_link_out"},{"id":"openfda:235dfc38-0f0b-4037-b501-7a9f4294740c:20260226","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-qvzn322kmcvd7xtnips5xaun-3mwg7horous2z","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vlu7phn7ukzdmfdklid6av5q-3mwzdcztmwc2h","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:fa58b5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1278052934161293312:ef6c09a1-458c-4f85-878d-03cd0d506427","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1575851193112272897:03cb38ff-a517-4e04-a95f-befa7488770e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1595958487947046913:a3cdb42e-3ea7-418c-ad8c-4eb52e959209","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716489446961414162:21617ae5-7698-4572-a7ba-e7197f705a7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1722620595442241915:f3ea44e9-4419-476d-b816-8c0b703a3952","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1806289198699221117:01b1b954-e0e0-4cec-bfa4-ea8b72004dd5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1829265047501308004:c8386cb5-87cb-46a9-8b09-6ac457aa2e91","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1961041528614162771:f7ba7453-286c-4e7f-a132-cb9788553249","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1974234205140799513:9ce0295c-3d61-46aa-bf63-0f765e5e8c2a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108916269890392115:245932cc-b91e-4fcd-80bd-1bc11dac1376","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110627388082258023:e50ad5e5-b613-4b4a-837d-f67da8a41b33","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112105220436119752:42d98794-9cc1-4f18-9bbd-5642908f34c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112178881478132160:963eda0e-5685-4324-b2bc-65df7e2cc6be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112984991609323557:9c223e09-5d05-453d-9fb5-230599c85c46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113975866271420555:7108363e-5030-4615-ad63-5e0428cdda73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113976400482861122:d01da34a-d7ec-4048-8e84-b909712384e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113977300861546877:79aee23d-0348-4fa6-91c3-c2e674c22f0b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113978004858868149:c95e4cc8-0358-4453-816f-49608465961b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113982327768727675:a5184107-dcec-40fc-b36a-7058dbf627ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113986074225660287:0552e2df-0d00-446b-8682-79cefe91435c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113987734079680801:0028f7f5-293c-4c0b-aaeb-d1be29c18e1c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114010706395689285:9fe8e450-343a-44aa-8ef9-2f40f0bb7a4a","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":22,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":25},"count":25,"evidence_window":{"end":"2026-10-24","start":"2020-06-30"},"retrieval_snapshot":"2026-10-28T21:22:01.808547Z","timeline":[{"count":1,"week":"2020-W27"},{"count":1,"week":"2022-W39"},{"count":1,"week":"2022-W47"},{"count":1,"week":"2023-W08"},{"count":1,"week":"2023-W34"},{"count":1,"week":"2023-W43"},{"count":1,"week":"2023-W45"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W35"},{"count":1,"week":"2025-W35"},{"count":1,"week":"2025-W40"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":2,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":12,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Erbitux"],"label":"cetuximab","slug":"cetuximab"},{"reason":"Unmapped registry intervention: encorafenib","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Colorectal cancer","slug":"colorectal-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"BRICKET","aliases":["BRICKET","Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC","Single Arm Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients With BRAF V600E Mutated mCRC (BRICKET)"],"brief_title":"Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC","collaborators":["Merck Sharp & Dohme LLC","Pierre Fabre Laboratories"],"conditions":["Colorectal Cancer"],"enrollment":{"count":16,"type":"ACTUAL"},"interventions":[{"name":"Cetuximab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Encorafenib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06578559","official_title":"Single Arm Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients With BRAF V600E Mutated mCRC (BRICKET)","overall_status":"COMPLETED","phase":["PHASE2"],"primary_completion_date":{"date":"2026-05-12","type":"ACTUAL"},"primary_endpoints":[{"description":"The percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria. The determination of clinical response will be based on investigator-reported measurements. Responses will be evaluated with a total body computed tomography (CT) scan every 8 weeks.","measure":"Objective Response Rate (ORR)","timeFrame":"8 months after the enrollment of the last patient."}],"registry_last_updated":"2026-10-28","registry_url":"https://clinicaltrials.gov/study/NCT06578559","short_name":"BRICKET","short_name_basis":"registry_acronym","sponsor":"Gruppo Oncologico del Nord-Ovest","start_date":{"date":"2024-07-23","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"BRICKET","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}